Arcadia Biosciences, Inc, an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits. It also provides nutritional oils comprising gamma linolenic acid safflower oil to manufacturers of dietary and nutritional supplements, medical foods, dog food, and other products under the SONOVA brand; and arachidonic acid safflower oil that is used as an ingredient in infant nutrition products.
Read More…
Industry, Sector and Symbol
Industry Agricultural chemicals
Sub-IndustryN/A
SectorBasic Materials
Phone530-756-7077
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.46 million
Profitability
Miscellaneous
Employees44
Next Earnings Date11/6/2019 (Estimated)
OptionableNot Optionable
Arcadia Biosciences (NASDAQ:RKDA) Frequently Asked Questions
What is Arcadia Biosciences' stock symbol?
Arcadia Biosciences trades on the NASDAQ under the ticker symbol "RKDA."
When did Arcadia Biosciences' stock split? How did Arcadia Biosciences' stock split work?
Arcadia Biosciences shares reverse split on the morning of Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 23rd 2018. An investor that had 100 shares of Arcadia Biosciences stock prior to the reverse split would have 5 shares after the split.
How were Arcadia Biosciences' earnings last quarter?
Arcadia Biosciences Inc (NASDAQ:RKDA) released its quarterly earnings results on Wednesday, August, 14th. The basic materials company reported ($0.96) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by $0.08. The basic materials company earned $0.20 million during the quarter, compared to analyst estimates of $0.20 million. Arcadia Biosciences had a negative net margin of 388.94% and a negative return on equity of 157.32%. View Arcadia Biosciences' Earnings History.
When is Arcadia Biosciences' next earnings date?
What price target have analysts set for RKDA?
2 Wall Street analysts have issued 1-year target prices for Arcadia Biosciences' stock. Their forecasts range from $14.00 to $20.00. On average, they expect Arcadia Biosciences' stock price to reach $17.00 in the next year. This suggests a possible upside of 220.8% from the stock's current price. View Analyst Price Targets for Arcadia Biosciences.
What is the consensus analysts' recommendation for Arcadia Biosciences?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcadia Biosciences.
What are Wall Street analysts saying about Arcadia Biosciences stock?
Here are some recent quotes from research analysts about Arcadia Biosciences stock:
- 1. National Securities analysts commented, " Second Quarter Results Meet Expectations. A $5.0 million operating loss fell in line with our $4.8 million estimates. GAAP earnings were skewed by a $9.5 million non-cash gain from warrant adjustments. Excluding this, earnings fell in line with estimates.
Cannabis Initiative Taking Off. The story of the earnings release was surprisingly not what has driven volume in recent days. The cannabis initiative is accelerating faster than we anticipated, with the company now expecting to derive near term revenue from sale of seed. We estimate this high margin product could conservatively deliver $3 to $5 million of revenue in 2020, with modest initial revenues coming in the fourth quarter of 2019.
HB4 Approved By USDA. On August 8th, the USDA announced its approval of the HB4 soybean to be grown domestically. This is a meaningful milestone and came 12 to 24 months before we anticipated. RKDA can now identify a commercial partner and integrate the trait into domestic germplasm with field trials likely to begin in 2021 and commercial revenue in 2023. While this is a faster timeline than we expected, it does not significantly alter our estimates or valuation.
Cannabis Value Still In Early Innings. We believe the most valuable revenue in agribusiness is derived from proprietary genetics, and we believe the most valuable crop in the market is cannabis. RKDA is engaged in breeding efforts to develop proprietary lines of cannabis, which we believe is a roughly 3 year process before commercialization can begin. For patient investors, we believe RKDA is in the process of generating significant value via these efforts, and we expect enhanced visibility of this potential over the next 12 to 24 months." (8/15/2019)
- 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. Our valuation utilizes a discounted cash flow-based approach that derives a $140M value for RS Wheat, using a 15% discount rate, 30% tax rate and 10% manufacturing spend. This translates into a price per share of $14.00, assuming roughly 10M shares outstanding as of end-1Q20." (6/6/2019)
- 3. According to Zacks Investment Research, "Arcadia Biosciences, Inc. is engaged in developing and commercializing agricultural products primarily in the United States. The Company's product includes nitrogen use crops, salt tolerant plants, sunflower oil and shelf-life produce. Arcadia Biosciences, Inc. is headquartered in Davis, California. " (2/14/2019)
Has Arcadia Biosciences been receiving favorable news coverage?
News articles about RKDA stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Arcadia Biosciences earned a news sentiment score of -1.3 on InfoTrie's scale. They also assigned news headlines about the basic materials company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Arcadia Biosciences.
Are investors shorting Arcadia Biosciences?
Arcadia Biosciences saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 1,697,500 shares, an increase of 1,790.3% from the July 31st total of 89,800 shares. Based on an average daily trading volume, of 2,750,000 shares, the short-interest ratio is currently 0.6 days. Currently, 36.3% of the company's shares are sold short. View Arcadia Biosciences' Current Options Chain.
Who are some of Arcadia Biosciences' key competitors?
What other stocks do shareholders of Arcadia Biosciences own?
Who are Arcadia Biosciences' key executives?
Arcadia Biosciences' management team includes the folowing people:
- Mr. Rajendra Ketkar, Pres, CEO & Director (Age 65)
- Mr. Matthew T. Plavan, CFO, Sec. & Pres of Arcadia Specialty Genomics (Age 55)
- Ms. Sarah Reiter, Chief Commercial Officer (Age 47)
- Dr. Randy Shultz Ph.D., Head of R&D
- Dr. Zhongjin Lu Ph.D., Director of Product Devel. (Age 53)
When did Arcadia Biosciences IPO?
(RKDA) raised $66 million in an initial public offering on Friday, May 15th 2015. The company issued 8,200,000 shares at $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO.
Who are Arcadia Biosciences' major shareholders?
Arcadia Biosciences' stock is owned by many different of retail and institutional investors. Top institutional investors include CVI Holdings LLC (2.15%), Vanguard Group Inc. (1.87%), Morgan Stanley (1.30%), Cambridge Investment Research Advisors Inc. (0.18%) and Citadel Advisors LLC (0.17%). Company insiders that own Arcadia Biosciences stock include Eric J Rey, Kevin Comcowich, Matthew T Plavan, Sarah Reiter and Zhongjin Lu. View Institutional Ownership Trends for Arcadia Biosciences.
Which institutional investors are buying Arcadia Biosciences stock?
RKDA stock was purchased by a variety of institutional investors in the last quarter, including CVI Holdings LLC, Morgan Stanley, Vanguard Group Inc., Cambridge Investment Research Advisors Inc. and Citadel Advisors LLC. Company insiders that have bought Arcadia Biosciences stock in the last two years include Kevin Comcowich, Matthew T Plavan and Sarah Reiter. View Insider Buying and Selling for Arcadia Biosciences.
How do I buy shares of Arcadia Biosciences?
Shares of RKDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Arcadia Biosciences' stock price today?
One share of RKDA stock can currently be purchased for approximately $5.30.
How big of a company is Arcadia Biosciences?
Arcadia Biosciences has a market capitalization of $38.69 million and generates $1.46 million in revenue each year. The basic materials company earns $-13,480,000.00 in net income (profit) each year or ($5.35) on an earnings per share basis. Arcadia Biosciences employs 44 workers across the globe.View Additional Information About Arcadia Biosciences.
What is Arcadia Biosciences' official website?
How can I contact Arcadia Biosciences?
Arcadia Biosciences' mailing address is 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018. The basic materials company can be reached via phone at 530-756-7077 or via email at [email protected]
MarketBeat Community Rating for Arcadia Biosciences (NASDAQ RKDA)
MarketBeat's community ratings are surveys of what our community members think about Arcadia Biosciences and other stocks. Vote "Outperform" if you believe RKDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RKDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
